File Archive - GHB & GBL Documents - Pharmacokinetics and Pharmacodynamics of GHB During Tolerance in Rats: Effects of Extracellular Dopamine (2007)

News Groups Blog Forum Chat Video Audio Images Documents Wiki Home

		Drugs Forum > File Archive > Documents > CHEMICAL & (SEMI-) SYNTHETIC DRUGS > GHB & GBL Documents
Pharmacokinetics and Pharmacodynamics of GHB During Tolerance in Rats: Effects of Extracellular Dopamine (2007)

Tags

FAQ n Rules

Mark Forums Read

Notices

Create a FREE account now to get access to more forums, more videos, more music, more documents, more images, more reviews, more news about drugs and much more functionality.
Start posting now, join our groups or create your unique profile.

links

GHB & GBL Documents

Documents about GHB, GBL, BDO, gamma-Hydroxybutyrate, Sodium Oxybate, Xyrem, gamma-Butyrlactone, 1,4-Butanediol

Allowances: 4.88 Mbytes/1.11 Mbytes used

[RSS Feed]

Entries

Pharmacokinetics and Pharmacodynamics of GHB During Tolerance in Rats: Effects of Extracellular Dopamine (2007)

Left click: open entry/Right click: save entry

Journal of Pharmacology and Experimental Therapeutics 2007 Mar;320(3):1252-60.

Raybon JJ, Boje KM

gamma-Hydroxybutyrate (GHB) is a potent sedative/hypnotic and drug of abuse. Tolerance develops to GHB's sedative/hypnotic effects. It is hypothesized that GHB tolerance may be mediated by alterations in central nervous system pharmacokinetics or neurotransmitter response. Rats were dosed daily with GHB (548 mg/kg s.c. q.d. for 5 days), and sleep time was measured as an index of behavioral tolerance. Plasma and brain GHB pharmacokinetics on days 1 and 5 were monitored using blood and microdialysis sampling. Extracellular (ECF) striatal dopamine levels were measured by microdialysis as a pharmacodynamic endpoint of tolerance. Pharmacokinetic (PK)/pharmacodynamic (PD) modeling was performed to describe the plasma and brain disposition using an indirect response model with inhibition of dopamine synthesis rate to describe the pharmacodynamic response. GHB plasma and brain ECF concentration versus time profiles following acute or chronic exposure were not significantly different. GHB sedative/hypnotic tolerance was observed by day 5. Acute GHB administration resulted in a decrease in striatal ECF dopamine (DA) levels compared with baseline levels. GHB tolerance was reflected by a 60% decrease in dopamine area under the curve (effect and baseline): acute, 10.1 +/- 15.3% basal DA/min/10(-3) versus chronic, 4.73 +/- 1.49% basal DA/min/10(-3) (p < 0.05, n = 5; unpaired Student's t test). The PK/PD model revealed an increase in the IC50 following chronic exposure indicating decreased dopaminergic sensitivity toward the inhibitory effects of GHB. Our findings indicate that GHB pharmacokinetics do not contribute to behavioral tolerance; however, changes in neurotransmitter responsiveness may suggest specific neurochemical pathways involved in the development and expression of tolerance.

Discussion Thread

Category GHB & GBL Documents

Submitted by Jatelka

20-06-2007
644.74 Kbytes Hits 13
Keywords: tolerance pharmacokinetics ghb dopamine

Category

Forum Jump

Sitelinks:	Site Functions:
Homepage Wiki Documents Image Gallery Audio Video Forum Blog Groups News	Site Rules Frequently Asked Questions Register to Participate Did you forget your password? All Threads

All times are GMT +1. The time now is 12:45.